-

DexCom Promotes Jake Leach to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating officer.

Leach has most recently served as chief technology officer at Dexcom since 2018, leading the organization’s research, product development, project management and engineering departments. An 18-year veteran of the company, Jake joined Dexcom in 2004 to lead the development of sensor electronics for the first commercial Dexcom CGM system. Since then, he has led the teams responsible for developing multiple generations of Dexcom CGM, including Dexcom G6, the best-selling real-time CGM in the world.

“For nearly two decades, Jake has helped lead technology development at Dexcom, ensuring our organization is on the forefront of innovation in continuous glucose monitoring and data connectivity,” said Kevin Sayer, chairman, president and chief executive officer at Dexcom. “In this new role, Jake will expand upon his proven leadership and industry expertise to ensure that Dexcom remains at the forefront of sensing technology and well-positioned to bring Dexcom CGM to the millions of additional people who stand to benefit from it.”

As chief operating officer, Leach will have end-to-end responsibility for product at Dexcom, driving day-to-day decision-making and resource allocation across all major product-facing groups. In addition, Jake will oversee several executive leadership functions, including global operations, research and development, quality management and regulatory, creating an integrated management structure that strengthens the company’s ability to execute on its vision for long-term sustainable growth.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

© 2022 Dexcom, Inc. Dexcom and Dexcom G6 are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:dxcm

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results...

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom...

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi...
Back to Newsroom